[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2022001626A - Composiciones biofarmaceuticas y procedimientos conexos. - Google Patents

Composiciones biofarmaceuticas y procedimientos conexos.

Info

Publication number
MX2022001626A
MX2022001626A MX2022001626A MX2022001626A MX2022001626A MX 2022001626 A MX2022001626 A MX 2022001626A MX 2022001626 A MX2022001626 A MX 2022001626A MX 2022001626 A MX2022001626 A MX 2022001626A MX 2022001626 A MX2022001626 A MX 2022001626A
Authority
MX
Mexico
Prior art keywords
related procedures
biopharmaceutical compositions
compositions
biopharmaceutical
bcma
Prior art date
Application number
MX2022001626A
Other languages
English (en)
Inventor
James K Kranz
Michael Joseph Molloy
Jr Joseph V Rinella
Elizabeth Rae Schmidt
Hillary Amber Schuessler
Tejash Shah
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71994687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022001626(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MX2022001626A publication Critical patent/MX2022001626A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/80Vaccine for a specifically defined cancer
    • A61K2039/804Blood cells [leukemia, lymphoma]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/55Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención aquí descrita proporciona composiciones que comprenden proteínas de unión a antígenos anti-BCMA y procedimientos relacionados para el tratamiento de enfermedades o trastornos mediados por la BCMA.
MX2022001626A 2019-08-06 2020-07-31 Composiciones biofarmaceuticas y procedimientos conexos. MX2022001626A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962883451P 2019-08-06 2019-08-06
US201962948432P 2019-12-16 2019-12-16
US202062984110P 2020-03-02 2020-03-02
PCT/IB2020/057267 WO2021024133A2 (en) 2019-08-06 2020-07-31 Biopharmacuetical compositions and related methods

Publications (1)

Publication Number Publication Date
MX2022001626A true MX2022001626A (es) 2022-03-02

Family

ID=71994687

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001626A MX2022001626A (es) 2019-08-06 2020-07-31 Composiciones biofarmaceuticas y procedimientos conexos.

Country Status (15)

Country Link
US (1) US20220289859A1 (es)
EP (1) EP4010372A2 (es)
JP (2) JP7515567B2 (es)
KR (1) KR20220041915A (es)
CN (2) CN120204384A (es)
AU (1) AU2020325753B2 (es)
BR (1) BR112022002236A2 (es)
CA (1) CA3146471A1 (es)
CL (1) CL2022000294A1 (es)
CO (1) CO2022002627A2 (es)
IL (1) IL290325A (es)
MX (1) MX2022001626A (es)
PH (1) PH12022550277A1 (es)
TW (2) TW202227142A (es)
WO (1) WO2021024133A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240040786A (ko) * 2021-08-03 2024-03-28 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 생물제약 조성물 및 안정한 동위원소 표지 펩티드 맵핑 방법
TW202413435A (zh) * 2022-08-05 2024-04-01 美商艾力克森製藥公司 融合蛋白的藥物組成物及其使用方法
WO2024121711A1 (en) 2022-12-05 2024-06-13 Glaxosmithkline Intellectual Property Development Limited Methods of treatment using b-cell maturation antigen antagonists

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
AU758240B2 (en) 1998-02-25 2003-03-20 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6374470B1 (en) 2000-10-06 2002-04-23 Milliken & Company Face plate for spun-like textured yarn
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
WO2002060919A2 (en) 2000-12-12 2002-08-08 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
CA2494105C (en) 2002-07-31 2013-04-02 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
EP3120861B1 (en) 2003-11-06 2018-08-15 Seattle Genetics, Inc. Intermediate for conjugate preparation comprising auristatin derivatives and a linker
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
KR101772354B1 (ko) 2010-04-15 2017-08-28 시애틀 지네틱스, 인크. 표적화된 피롤로벤조디아제핀 접합체
UA112434C2 (uk) * 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
MY177970A (en) 2011-05-27 2020-09-28 Glaxo Group Ltd Bcma (cd269/tnfrsf17) -binding proteins
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對bcma之e3以及cd3的結合分子
EA033110B1 (ru) 2012-04-11 2019-08-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы
JP6694712B2 (ja) 2012-11-01 2020-05-20 マックス−デルブルック−セントラム フアー モレキュラーレ メデジン Cd269(bcma)に対する抗体
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Bcma抗原結合蛋白質
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
EP2953974B1 (en) 2013-02-05 2017-12-20 EngMab Sàrl Bispecific antibodies against cd3epsilon and bcma
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
EP2968589A1 (en) 2013-03-15 2016-01-20 AbbVie Inc. Antibody drug conjugate (adc) purification
GB201317928D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Molecule
JP6529188B2 (ja) 2013-11-25 2019-06-12 シアトル ジェネティックス, インコーポレイテッド コンジュゲーションのためのcho細胞培養物からの抗体の調製
JP6698546B2 (ja) 2014-04-14 2020-05-27 セレクティスCellectis 癌免疫療法のためのbcma(cd269)特異的キメラ抗原受容体
JP6285274B2 (ja) 2014-04-28 2018-02-28 株式会社ブリヂストン バイアスタイヤ及びその製造方法
RU2751660C2 (ru) 2014-07-21 2021-07-15 Новартис Аг Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма
ES2878449T3 (es) 2014-07-24 2021-11-18 2Seventy Bio Inc Receptores antigénicos quiméricos de BCMA
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
CA2969870A1 (en) 2014-12-05 2016-06-09 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
NZ732568A (en) 2014-12-05 2023-03-31 Memorial Sloan Kettering Cancer Center Antibodies targeting b-cell maturation antigen and methods of use
HUE057285T2 (hu) * 2015-04-13 2022-04-28 Pfizer Terápiás ellenanyagok és alkalmazásaik
WO2017021450A1 (en) 2015-08-03 2017-02-09 Engmab Ag Monoclonal antibodies against bcma
EP3147954A1 (en) 2015-09-22 2017-03-29 Nokia Technologies Oy Photodetector with conductive channel made from two dimensional material and its manufacturing method
BR112020005077A2 (pt) * 2017-09-14 2020-09-15 Glaxosmithkline Intellectual Property Development Limited tratamento de combinação para câncer
EP3700540A4 (en) * 2017-10-24 2021-11-10 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS OF DEPRODUCTION FROM CD117 + CELLS

Also Published As

Publication number Publication date
KR20220041915A (ko) 2022-04-01
CO2022002627A2 (es) 2022-04-08
AU2020325753A1 (en) 2022-03-03
CN114502593A (zh) 2022-05-13
AU2020325753B2 (en) 2025-03-13
TW202227142A (zh) 2022-07-16
IL290325A (en) 2022-04-01
CL2022000294A1 (es) 2022-10-07
JP7515567B2 (ja) 2024-07-12
CN120204384A (zh) 2025-06-27
CA3146471A1 (en) 2021-02-11
PH12022550277A1 (en) 2022-11-21
US20220289859A1 (en) 2022-09-15
TWI867020B (zh) 2024-12-21
BR112022002236A2 (pt) 2022-05-03
JP2024056791A (ja) 2024-04-23
WO2021024133A3 (en) 2021-03-25
WO2021024133A2 (en) 2021-02-11
TW202120549A (zh) 2021-06-01
JP2022543273A (ja) 2022-10-11
EP4010372A2 (en) 2022-06-15

Similar Documents

Publication Publication Date Title
MX2023015185A (es) Degradadores de proteinas y usos de los mismos.
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
CO2019004003A2 (es) Composiciones y anticuerpos anti-lag-3
CL2021000343A1 (es) Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128)
CL2022000294A1 (es) Composiciones biofarmacéuticas y procedimientos conexos.
MX2022010229A (es) Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
BR112019011689A2 (pt) tratamento de uma doença do trato gastrointestinal com um inibidor de tnf
CL2024000459A1 (es) Tubulisinas y conjugados de proteína-tubulisina.
CO2019014286A2 (es) Bis-octahidrofenantreno carboxamidas y conjugados de proteína de las mismas
BR112018000542A2 (pt) composições de irna de transtirretina (ttr) e métodos de uso das mesmas para o tratamento ou prevenção de doenças associadas à ttr
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
BR112017026467A2 (pt) uso de exossomos para o tratamento de doença
BR112019010595A2 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto.
AR110114A1 (es) ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS
BR112018074978A2 (pt) anticorpos para alfa-sinucleína e usos dos mesmos
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
BR112017021484A2 (pt) anticorpos de direcionamento à proteína morfogenética óssea 9 (bmp9) e métodos para os mesmos
BR112017012381A2 (pt) imunoterapia para doença angiogênica
BR112018072118A2 (pt) anticorpos de interferona beta e usos dos mesmos
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).
CL2021002795A1 (es) Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares
IL311256A (en) Methods and uses of microbiome compositions, components, or metabolites for treating neurodegenerative diseases
BR112021017810A2 (pt) Anticorpos tsg-6 e usos dos mesmos
CY1124258T1 (el) ΕΝΩΣΕΙΣ ΧΡΗΣΙΜΕΣ ΓΙΑ ΑΝΑΣΤΟΛΗ ROR-γ-t
BR112018012126A2 (pt) ?adjuvante, método para prevenir e/ou tratar uma doença autoimune, e, uso de um adjuvante?